<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831947</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002ADE09T</org_study_id>
    <nct_id>NCT01831947</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.</brief_title>
  <acronym>RABIMO</acronym>
  <official_title>Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial investigates the impact of intravitreal injection of Ranibizumab antibody&#xD;
      on the acuteness of vision. Patients included are suffering from choroidal&#xD;
      neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD).&#xD;
&#xD;
      Initially, all patients get injections of 0.5 mg Ranibizumab in monthly intervals for 3&#xD;
      months. Subsequently, one group gets Ranibizumab in intervals of 2 months, whereas a second&#xD;
      group is treated on demand.&#xD;
&#xD;
      The primary end point of the study is the change of best-corrected visual acuity after 12&#xD;
      month.&#xD;
&#xD;
      Secondary end points include the impact of Ranibizumab on morphological changes of the&#xD;
      retina, the number of patients with gain or loss of 15 or more letters visual acuity after 12&#xD;
      months, changes in quality of life and the number of injections required during the first 12&#xD;
      months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>best-corrected visual acuity</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Change of best-corrected visual acuity before and 12 months after start of treatment with respect to number of letters read on ETDRS-sheets (Early Treatment Diabetes Retinopathy Study Sheets).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluoresceinangiography</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>To study morphological and anatomical changes of the retina. Affected area is determined in mm²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photography</measure>
    <time_frame>12 months after treatment start</time_frame>
    <description>To study morphological and anatomical changes of the retina. Affected area is assessed by computer-assisted measurement in mm².</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optical coherence tomography (OCT)</measure>
    <time_frame>12 months after treatment start</time_frame>
    <description>To study morphological and anatomical changes of the retina. Thickness of the retina is determined in µm².</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of injections</measure>
    <time_frame>12 months after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 months after treatment start</time_frame>
    <description>change in quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab fixed dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab on demand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <arm_group_label>Ranibizumab fixed dose</arm_group_label>
    <arm_group_label>Ranibizumab on demand</arm_group_label>
    <other_name>Lucentis (Novartis Pharma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with choroidal neo-vascularization (CNV) as a consequence of age-related&#xD;
             macular degeneration (AMD)&#xD;
&#xD;
          -  age 50 and older, male and female&#xD;
&#xD;
          -  membrane &lt;= 12 papillary diameter&#xD;
&#xD;
          -  visual acuity between 20/320 and 20/40 (ETDRS)&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitivity to the medicinal product under investigation, ingredients or&#xD;
             medicinal products with a similar chemical structure&#xD;
&#xD;
          -  participation in another clinical trial within the last 4 weeks&#xD;
&#xD;
          -  unability to understand trial information&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  women with an amenorrhea &lt; 12 months&#xD;
&#xD;
          -  suspected unability to cooperate&#xD;
&#xD;
          -  detachment of pigment epithelium without membrane detection &gt;= 50%,retinal&#xD;
             angiomatotic proliferation (RAP), presumed ocular histoplasmosis syndrome (POHS),&#xD;
             chorioretinal anastomosis (CRA), myopic CNV, CNV following trauma, uveitis, RCS or&#xD;
             reasons except AMD&#xD;
&#xD;
          -  rupture of pigment epithelium&#xD;
&#xD;
          -  sub-retinal bleeding &gt;= 50% of membrane or &gt;= 1 PD&#xD;
&#xD;
          -  sub-retinal fibrosis or chorio-atrophy&#xD;
&#xD;
          -  pre-treatment with Verteporfin (photodynamic therapy), radiotherapy, trans-pupillary&#xD;
             thermotherapy of the eye under investigation as a consequence of maculadegeneration&#xD;
             treatment with Verteporfin of the eye not under investigation within 7 days prior&#xD;
             inclusion&#xD;
&#xD;
          -  former participation in clinical trials with anti-angiogenic substances: Pegaptanib,&#xD;
             Ranibizumab, Bevacizumab, Anecortave Acetat, Proteinkinase C Inhibitors&#xD;
&#xD;
          -  former injection of anti-angiogenic substances in the eye under investigation&#xD;
&#xD;
          -  former focal sub-foveal lasercoagulation of the eye under investigation&#xD;
&#xD;
          -  juxta- or extra-foveal lasercoagulation of the eye under investigation within 1 month&#xD;
             prior inclusion&#xD;
&#xD;
          -  former vitrectomy&#xD;
&#xD;
          -  former surgery as a consequence of maculadegeneration&#xD;
&#xD;
          -  glaucoma patients which have been treated with prostaglandin containing eye drops&#xD;
&#xD;
          -  other ocular diseases which may lead to surgery within the clinical study or may lead&#xD;
             to a loss of vision of two lines&#xD;
&#xD;
          -  acute intraocular inflammation of the eye under investigation&#xD;
&#xD;
          -  vitreous hemorrhage of the eye under investigation&#xD;
&#xD;
          -  macula-foramen of the eye under investigation&#xD;
&#xD;
          -  diabetic retinopathy&#xD;
&#xD;
          -  former retina detachment of the eye under investigation&#xD;
&#xD;
          -  uveitis&#xD;
&#xD;
          -  acute conjunctivitis, keratitis, scleritis, or endophthalmitis&#xD;
&#xD;
          -  aphakia or pseudo-aphakia with damaged back-capsule(exception: YAG-capsulotomy)&#xD;
&#xD;
          -  myopia larger than -8 diopter&#xD;
&#xD;
          -  former intra-ocular surgery of the eye under investigation within 2 months prior&#xD;
             inclusion&#xD;
&#xD;
          -  de-compensated glaucoma with &gt;= 30 mm Hg despite therapy&#xD;
&#xD;
          -  former filtrating glaucoma surgery of the eye under investigation&#xD;
&#xD;
          -  former corneal grafting of the eye under investigation&#xD;
&#xD;
          -  former stroke or heart attack&#xD;
&#xD;
          -  on-going therapy because of systemic infection&#xD;
&#xD;
          -  known allergic reaction to fluorescein&#xD;
&#xD;
          -  bad quality of fundus documentation because of bad range of vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>age-related macular degeneration</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

